Target & Activity
| Target | Activity | Value |
|---|---|---|
| NF-κB | ||
| Autophagy |
Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| K562 | IC50 | 11.1 μM | Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay | [PMID: 35551036] |
| K562 | IC50 | 17.1 μM | Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay | [PMID: 35551036] |
| K562 | IC50 | 8.93 μM | Cytotoxicity against human imatinib-resistant K562 leukemia cells expressing p210Bcr/Abl and MDR1 at 48 hrs by MTT assay | [PMID: 19285759] |
| KB | ED50 | 9210 nM | Cytotoxicity against human KB cells after 72 hrs by SRB assay | [PMID: 9917283] |
| U-937 | IC50 | > 50 μM | Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay | [PMID: 22766217] |
| Vero | CC50 | > 50 μM | Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr | 10.1101/2020.03.20.999730 |
| Vero | IC50 | 7.87 μM | Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr | 10.1101/2020.03.20.999730 |